Johnson & Johnson stock gapped down Wednesday after the health care giant issued light 2025 sales guidance, taking a hit from exchange rates.
The Dow Jones rose Wednesday on President Trump's $500 billion Stargate AI project. Netflix stock soared 14% on earnings.
The Dow Jones and other indexes jumped in the stock market today as investors await Inauguration Day on Monday. Bitcoin ...
In midday trading, the Dow Jones Industrial Average fell 57 points, or 0.1%, to 44,507. The S&P 500 edged up 0.1%, and the Nasdaq was flat. All three major indexes are on pace for their second ...
The Dow Jones Industrial Average plunged more than 650, or 1.52%, to 42,340.69, shortly after the opening bell, while the S&P 500 lost 89.52 points, or 1.51%, to 5,881.32 and the Nasdaq ...
Chairman Tim Martin said Wednesday that forecasting was more difficult due to increased costs but that the company remained confident of a reasonable outcome for the year. J.D. Wetherspoon expects ...
The 10-year yield is down 4.5 (basis points) to 1.63%." The S&P 500 gained 0.3% to set a new record close at 4,141, and the Dow Jones Industrial Average finished slightly lower, off 0.2% to 33,677.
The Dow was crushing the other major indexes to start the day on Monday. The blue-chip index was up 200 points, or 0.5%, while the S&P 500 was down 0.5%. The Nasdaq Composite was down 1.2%. The Dow ...
Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...
Stocks were mostly higher on Tuesday, overcoming a bumpy session ahead of tomorrow's consumer price index. The S&P 500 rose 0.1%. The Nasdaq Composite was down 0.2%. The Dow rose 221 points, or 0.5%.
Stock futures ticked lower on Thursday night after the Dow Jones Industrial Average and the S&P 500 ended a three-day losing streak. Futures tied to the 30-stock Dow fell 41 points, or 0.1%. S&P 500 ...
The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...